New extension study data with Novartis drug Gilenya® shows patients successfully treated for up to 7 years in relapsing MS Novartis, 19 Apr 2012 Accessed on 16 May 2012 from http://www.novartis.com/newsroom/media-releases/en/2012/1604172.shtml. CommentRecommendBookmarkWatch